Silence Therapeutics PLC - novel RNA therapeutics developer with offices in London and Berlin - Starts dosing in the Apollo phase I clinical study of SLN360 for the treatment of elevated lipoprotein. A high level of lipoprotein means an individual is at risk of developing heart disease. Notes trial comprised 88 people is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated lipoprotein, adding it expects data from the single-ascending dose portion of the study to be published in the second half of 2021.
Current stock price: 602.00 pence
Year-to-date change: up 17%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
